Real-World data reveals how bosutinib fights leukemia outside clinical trials

NCT ID NCT05363488

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study looks back at medical records from a single hospital in Scotland to see how well the drug bosutinib works and how safe it is for people with chronic myeloid leukemia (CML) in everyday practice. Researchers will track blood cell counts, genetic responses, and side effects in 17 patients who took bosutinib as part of their normal care. The goal is to understand the drug's real-world effectiveness beyond the controlled conditions of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bosutinib
What this could lead to
If successful, this study could provide a clearer picture of how bosutinib performs outside of controlled trials, helping doctors make better treatment decisions for people with chronic myeloid leukemia.
What could go wrong
This is a small, retrospective study at a single center, so results may not apply to all patients. It only describes what happened in the past, not a controlled experiment, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eatson West of Scotland Cancer Center

    Glasgow, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.